Fig. 1: Profiles of the subcellular distribution of Kaiso (ZBTB33) show that nuclear and cytoplasmic Kaiso are differentially correlated with breast cancer subtype and hormone status.

a Representative subcellular patterns of Kaiso expression in breast cancer tissues detected by anti -Kaiso immunohistochemical staining. Shown is a range of high (upper panels) versus low (bottom panel) nuclear and cytoplasmic protein expression. b Comparison of the distribution of digitally determined H-scores for nuclear versus cytoplasmic Kaiso enrichment. The difference in distribution is shown in contrast to the similarities in the distribution of nuclear versus cytoplasmic androgen receptor (AR). c Cytoplasmic Kaiso is differentially enriched in ER⁻ breast cancers compared to nuclear Kaiso and is significantly enriched in the more aggressive breast cancer subtypes, LumB, HER2⁺, and TNBC. d Nuclear and cytoplasmic levels of Kaiso (H-score) do not show significant differences (t-test) based on race (also see Supplementary Fig. 1). e Kaiso (ZBTB33) mRNA abundance (median) is predictive of poor overall breast cancer survival as demonstrated in two independent publicly available breast cancer cohorts⁸⁸. f Comparison of nuclear and cytoplasmic levels of Kaiso in breast cancer patients to levels detected by RNA-seq in (N = 131) patients demonstrates that Kaiso (ZBTB33) mRNA levels do not correlate with either nuclear or cytoplasmic levels of Kaiso. LumA Luminal A, LumB Luminal B, HER2⁺ human epidermal growth factor receptor 2 positive, TNBC triple-negative BC, ER estrogen-receptor status, NHW non-Hispanic White, NHB non-Hispanic White.